Scientists have achieved a significant milestone by drilling the deepest hole ever into Earth’s mantle, obtaining a large rock sample from 4,160 feet (1,268 meters) below the Atlantic seabed. This breakthrough provides new insights into the mantle, which makes up over 80% of the planet’s volume.

Key Findings and Details

• Drilling Location: The sample was taken from the Atlantis Massif, an underwater mountain in the Atlantic Ocean. This area is known for exposing mantle rock at the seafloor.
• Drilling Depth: Researchers used the ocean drilling vessel JOIDES Resolution to drill approximately 2,800 feet (850 meters) beneath the ocean surface from April to June 2023.
• Sample Size: The core sample recovered is 2,907 feet (886 meters) long, marking a record for mantle rock drilling.

Scientific Insights

• Composition and Interaction: The cylindrical core sample provides valuable information about the composition of the upper mantle and the chemical interactions between mantle rock and seawater. These interactions might have played a crucial role in the origin of life on Earth billions of years ago.
• Historical Context: Previous drilling attempts have been limited to no deeper than 656 feet (200 meters) and had low rock recovery rates. The recent success marks a substantial improvement.

Research Significance

• Geological Understanding: This study enhances our knowledge of Earth’s mantle, a layer situated between the crust and the core, and its role in the planet’s geological and biological processes.
• Future Exploration: The findings could inform future research and exploration efforts, potentially offering more clues about the conditions that led to the emergence of life on Earth.

Expert Comment

• Johan Lissenberg (Cardiff University): The lead author of the study highlighted the significance of this drilling achievement, noting the increased depth and quality of the mantle rock recovery compared to previous attempts.

Transforming Mars into a more habitable world is a staple of science fiction, but scientists are exploring a practical approach to make this a reality. Researchers have proposed using engineered particles, similar in size to glitter, to warm Mars by trapping heat and scattering sunlight.

Key Proposal Details

• Concept: Use iron or aluminum nanoparticles as aerosols to enhance the greenhouse effect on Mars.
• Goal: Increase Mars’ surface temperature by approximately 50°F (28°C) over a decade.
• Purpose: This warming is a preliminary step toward making Mars more habitable, though it won’t immediately support human life.

How It Works

• Nanoparticles: Tiny, rod-shaped particles would be released into the Martian atmosphere. These particles would trap heat and reflect sunlight, gradually warming the planet.
• Release Rate: About eight gallons (30 liters) of nanoparticles per second would be introduced over several years.
• Material Sourcing: Iron and aluminum are abundant on Mars, suggesting the particles could be produced on-site.

Benefits and Challenges

• Current Temperature: Mars’ average surface temperature is about -85°F (-65°C). The proposed method aims to raise this temperature to allow for the potential presence of liquid water.
• Scientific Interest: This approach could make future Mars exploration more feasible and provide insights into the planet’s climate.

Expert Insights

• Edwin Kite (University of Chicago): Highlighted the novelty and efficiency of using nanoparticles compared to previous greenhouse gas methods. He noted that this proposal could inform future Mars exploration strategies.
• Samaneh Ansari (Northwestern University): Emphasized the feasibility of warming Mars using locally available materials and encouraged further exploration of this idea.

Environmental and Ethical Considerations

• Potential Risks: Scientists are cautious about unintended consequences, such as the impact on any existing Martian life forms or the potential toxicity of Martian soil.
• Exploration of Life: Researchers are also interested in whether Mars has, or ever had, life forms, which could influence the ethical considerations of terraforming.

Future Steps

• NASA’s Role: NASA continues to explore Mars with robotic missions and plans future human missions as part of its Artemis program.
• Public and Scientific Engagement: The proposal aims to spark interest and discussion within the scientific community and the public about the possibilities of altering Mars’ climate.

Canada has announced it will fund an Indigenous-led health study to investigate the effects of oil sands development on local communities. The decision follows recent concerns over pollution after a tailings water leak from an Imperial Oil site.

Key Details

• Funding: C$12 million ($8.71 million) over 10 years
• Study Name: Fort Chipewyan Health Study
• Focus: Assessing potential health risks, including cancer, for communities downstream of the oil sands region

Background

Fort Chipewyan, located in Northern Alberta, has been a focal point for health concerns related to oil sands operations. Last year, it was revealed that tailings water— a toxic mix of bitumen, sand, and residual bitumen— had been leaking from Imperial Oil’s Kearl mining site for months.

Health Issues Reported:

• Higher rates of cancer
• Autoimmune diseases
• Skin irritations
• Severe arthritis

Chief Allan Adam of the Athabasca Chipewyan First Nation highlighted that his community first called for a health study in 1992.

Government Response

• Environment Minister Steven Guilbeault: Emphasized the need for stronger environmental and health measures if the study shows negative impacts.
• Ottawa’s Invitation: The Alberta government was invited to help fund the study but has not yet responded.

Industry Reaction

• Imperial Oil: Expressed support for the study and regrets the recent tailings seepage.
• Pathways Alliance: The group of Canada’s major oil sands producers supports the study and respects the desire to gather information on health impacts.

Community Reaction

• Chief Billy-Joe Tuccaro: Criticized the delay in addressing these issues, stating that health concerns should have been addressed much earlier.

The study aims to provide robust data on the health and environmental impacts of oil sands operations. It will be developed with specific objectives determined by the communities affected.

Bangladesh’s interim leader, Muhammad Yunus, has announced the new council of advisors and taken control of 27 key ministries. Yunus, who was sworn in as chief advisor—a role similar to a prime minister—on Thursday, has assumed responsibility for a broad range of portfolios, including defense and public administration.

Key Appointments

• Foreign Ministry: Mohammad Touhid Hossain, a former foreign secretary, will lead the foreign ministry.
• Home Ministry: Retired Army Brigadier General M Sakhawat Hossain will oversee the home ministry.
• Finance and Planning Ministries: Salahuddin Ahmed, the former Bangladesh Bank governor, has been appointed.
• Local Government Ministry: A F Hassan Arif, a former attorney general, will manage this ministry.
• Telecommunications and IT: M Nahid Islam, a student leader, will be in charge.
• Youth and Sports: Asif Mahmud, another student leader, will take this role.

Background

Muhammad Yunus, 84, took over from Sheikh Hasina, who resigned and fled to India amid violent protests against her government’s controversial quota system for jobs. The unrest led to the formation of Yunus’s interim government, which has been visibly supported by the military.

Yunus has decided to personally manage several key ministries, including:

• Defense
• Public Administration
• Education
• Energy
• Food
• Water Resources
• Information

Unfilled Positions

Three members of the advisors’ council, primarily from civil society, were unable to take their oaths due to their absence from the capital. It is anticipated that Yunus might redistribute some of the 27 ministries to these members.

US Republican presidential candidate Donald Trump has confirmed he will debate his Democratic opponent Kamala Harris on September 10, hosted by ABC. Trump has also proposed additional debates on September 4 and September 25, which would be aired on Fox and NBC, respectively. This will be the first direct face-off between Trump and Harris, highlighting a highly competitive race.

Polls Overview

Ipsos Poll

• August 9 Survey:
  • Kamala Harris leads Donald Trump 42% to 37% for the upcoming November 5 elections.
  • This marks a rise in Harris’s popularity compared to the July 22-23 Reuters/Ipsos survey, where she led Trump 37% to 34%.
• Seven Key States:
  • Harris leads Trump 42% to 40% in states pivotal in the 2020 election: Arizona, Georgia, Michigan, Nevada, North Carolina, Pennsylvania, and Wisconsin.

YouGov Poll

• August 4 Findings:
  • Harris has overtaken Trump with a 1% lead nationwide, reversing Trump’s previous five-point advantage over Biden.
  • The poll indicates a tie between Harris and Trump in key swing states.
  • Mental Competence Perception:
    • 51% of respondents view Trump as mentally capable of the presidency, compared to 64% for Harris.

Marist Poll

• NPR/PBS News/Marist Survey:
  • Harris has a narrow 51% to 48% lead over Trump among crucial demographics including Black voters, white women with college degrees, and political independents.
  • Independent Women Voters:
    • Harris leads by 9 points (53% to 44%) among independent women, a key swing voter group.
  • Suburban and White Voters:
    • Harris has made notable gains in these groups, improving her standing.

Issue-Based Polling

• Economic Issues:
  • Trump leads Harris by 3 points (51% to 48%).
• Immigration:
  • Trump has a 52% to 46% advantage over Harris.
• Abortion:
  • Harris holds a significant lead with a 15-point advantage over Trump.

Kamala Harris, who joined the presidential race on July 21 after President Joe Biden’s endorsement, has selected Tim Walz, the Governor of Minnesota, as her running mate. Biden exited the race following a challenging debate performance against Trump on June 27.

The U.S. Food and Drug Administration (FDA) has given the green light to Citius Pharmaceuticals’ new therapy, Lymphir, for treating a rare form of blood cancer known as cutaneous T-cell lymphoma. This approval comes a year after the FDA initially rejected the treatment.

Key Details

• Treatment Overview
  • Name: Lymphir
  • Type: Therapy for cutaneous T-cell lymphoma
  • Target Patients: Adults with relapsed cutaneous T-cell lymphoma who have received at least one prior treatment
  • Prevalence: About 2,500 to 3,000 new cases annually in the U.S.
• Approval and Launch
  • Initial Rejection: July of the previous year due to a need for additional testing data
  • Launch Timeline: Planned within the next five months
  • Pricing: Expected to be in line with existing market treatments
• Safety Concerns
  • Boxed Warning: The FDA’s prescribing information includes a serious warning for capillary leak syndrome, a rare condition that causes blood plasma to leak from small blood vessels and results in a rapid drop in blood pressure.
• Market Context
  • Existing Treatments: Includes Bristol Myers Squibb’s Istodax and Bausch Health’s Targretin
  • Company’s Response: CEO Leonard Mazur expressed confidence that the boxed warning will not significantly hinder the therapy’s adoption, as both patients and physicians are aware of the risks.
• Company Plans
  • New Launch Unit: Lymphir will be introduced through Citius Oncology, which is set to go public soon through a SPAC deal.

The U.S. Food and Drug Administration (FDA) has approved ARS Pharmaceuticals’ new nasal spray, neffy, as an alternative to the traditional EpiPen for emergency allergic reactions. This approval marks the first needle-free treatment for potentially fatal allergic reactions.

Key Details

• Product Overview
  • Name: Neffy
  • Form: Nasal spray
  • Use: Single-dose spray administered into one nostril
  • Target Users: Approved for both adults and pediatric patients weighing at least 30 kilograms
• Availability and Pricing
  • Expected Release: Within eight weeks of FDA approval
  • Price: $199 for two doses through digital pharmacy sites like BlinkRx and GoodRx for uninsured patients
  • Co-Pay Savings: Some commercially insured patients can obtain neffy for $25 per prescription through a co-pay savings program
• Benefits and Accessibility
  • Needle-Free: Offers a non-injection alternative to EpiPen and other autoinjectors filled with epinephrine
  • Reduced Barriers: Aims to make treatment more accessible for those who fear needles, particularly children
• Medical Context
  • Condition: Anaphylaxis is a severe, life-threatening allergic reaction that affects multiple parts of the body and requires immediate medical attention.

Kelly Stone, an associate director at the FDA’s Center for Drug Evaluation and Research, highlighted that the nasal spray could help overcome reluctance to use injectable treatments, potentially improving access to life-saving medication.

Eli Lilly’s strong second-quarter performance has exceeded expectations, driven by booming sales of its diabetes medication Mounjaro and weight loss injection Zepbound. The company has significantly raised its revenue outlook and reported a substantial increase in earnings.

Key Highlights

• Earnings and Revenue
  • Earnings per Share (EPS): $3.92 (adjusted), surpassing the $2.60 forecast.
  • Revenue: $11.30 billion, exceeding the $9.92 billion estimate.
  • Net Income: $2.97 billion ($3.28 per share), up from $1.76 billion ($1.95 per share) a year earlier.
• Revenue Outlook
  • Eli Lilly has increased its full-year revenue guidance to between $45.4 billion and $46.6 billion, up by $3 billion at both ends of the range.
  • The company also raised its full-year adjusted earnings forecast to $16.10 to $16.60 per share, from the previous range of $13.50 to $14 per share.
• Drug Sales
  • Mounjaro: Generated $3.09 billion in sales, more than triple the amount from the same period last year. Analysts had expected $2.39 billion.
  • Zepbound: Achieved $1.24 billion in sales, well above the anticipated $922.2 million.
• Supply and Demand
  • Despite previous supply issues, all doses of Zepbound and Mounjaro are now available in the U.S. after extended shortages.
  • Eli Lilly has ramped up production, with plans to increase output of incretin drugs by 50% in the latter half of 2024 compared to the previous year.
• Future Outlook
  • Eli Lilly is working on developing more convenient weight loss pills to meet growing demand.
  • The company has built six new manufacturing plants and hired thousands of workers to boost production.
• Stock Performance
  • Shares of Eli Lilly closed over 9% higher on Thursday and have risen more than 30% this year, following a nearly 60% increase in 2023.

Market Context

Eli Lilly’s success with Mounjaro and Zepbound contrasts with challenges faced by competitors. Novo Nordisk reported weaker-than-expected sales for its weight loss drug Wegovy and diabetes injection Ozempic, partly due to pricing pressures.

A tragic plane crash occurred near Sao Paulo, Brazil, on Friday, resulting in the presumed death of all 62 people aboard. The aircraft, operated by Voepass, crashed shortly after taking off from Cascavel, heading for Sao Paulo’s main international airport.

Details

• Crash Location and Impact
  • The crash happened in Vinhedo, approximately 80 km (50 miles) northwest of Sao Paulo.
  • Social media footage captured the plane descending behind trees followed by a significant plume of black smoke.
• Aircraft Information
  • The plane involved was an ATR 72-500 turboprop, registered under PS-VPB.
  • ATR is a joint venture between Airbus and Italian aerospace company Leonardo.
• Response and Investigation
  • Voepass, the airline operating the flight, has not yet provided information on the cause of the crash.
  • Brazilian President Luiz Inacio Lula da Silva, at an event, requested a moment of silence for the victims and confirmed that all individuals on board are presumed dead.
• Current Status
  • The cause of the crash is under investigation. Further details are expected as the inquiry progresses.

Dozens of Russian military personnel are currently being trained in Iran to operate the Fath-360 close-range ballistic missile system. This development comes as both countries prepare for the imminent delivery of hundreds of these satellite-guided weapons to Russia for use in the ongoing conflict in Ukraine.

Key Points

• Training and Delivery
  • Russian military personnel have been in Iran for training on the Fath-360 missile system. The system has a maximum range of 120 km (75 miles) and carries a 150 kg warhead.
  • The training is expected to precede the delivery of the missiles to Russia. Sources suggest that the actual delivery could happen soon.
• Contracts and Agreements
  • On December 13, the Russian Defence Ministry is reported to have signed a contract with Iranian officials in Tehran. This agreement includes the purchase of the Fath-360 and another ballistic missile system known as the Ababil, produced by Iran’s Aerospace Industries Organization.
• Impact on the Conflict
  • The addition of Fath-360 missiles could enhance Russia’s capabilities by allowing the use of its own ballistic missiles for longer-range targets. The Iranian missiles would be used for closer-range engagements.
  • The deployment of these missiles could alter the dynamics of the conflict in Ukraine, potentially giving Russia more flexibility in its military strategy.
• Background
  • The Fath-360 is a close-range ballistic missile system designed for precision strikes. Its deployment marks a significant step in military cooperation between Russia and Iran, especially given the ongoing conflict in Ukraine and the broader geopolitical implications.